Tags

Type your tag names separated by a space and hit enter

The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children.
Pediatr Blood Cancer. 2009 May; 52(5):571-4.PB

Abstract

BACKGROUND

The aim of nutritional therapy in cancer patients is to prevent weight loss and to improve functional capacity and quality of life. Clinical studies however, have continued to demonstrate that a reduction in body weight loss is difficult to achieve in cancer cachexia. Several studies have shown that supplementation with eicosapentaenoic acid (EPA), an omega-3 fatty acid, has anti-cachectic effects in adult cancer patients. This study evaluated the clinical effects of a protein and energy dense EPA containing nutritional supplement in a group of pediatric cancer patients receiving active chemotherapy treatment.

METHODS

The study was a prospective, randomized, single center, open-label design. Fifty-two patients diagnosed with pediatric malignant disease and receiving intensive chemotherapy were included. Thirty-three patients received a nutritional supplement containing EPA in addition to their regular food intake. Nineteen control patients did not receive supplementation. Patients were examined and their data (body weight, body mass index, and weight percentile) were recorded regularly once a month for 3 months. A subgroup of patients was evaluated for 6 months.

RESULTS

At 3 months, there were significantly fewer patients in the treatment group as compared to controls that showed losses in body weight (P = 0.001), BMI (P = 0.002), and a negative deviation in weight percentile (P = 0.021). In addition, remission rate was significantly (P = 0.036) higher in the treatment group as compared to controls.

CONCLUSIONS

This study demonstrates a decrease in cancer-induced weight loss in pediatric patients fed a protein and energy dense nutrition supplement containing EPA.

Authors+Show Affiliations

Cukurova University Medical Faculty, Division of Pediatric Oncology, Adana, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19090549

Citation

Bayram, Ibrahim, et al. "The Use of a Protein and Energy Dense Eicosapentaenoic Acid Containing Supplement for Malignancy-related Weight Loss in Children." Pediatric Blood & Cancer, vol. 52, no. 5, 2009, pp. 571-4.
Bayram I, Erbey F, Celik N, et al. The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. Pediatr Blood Cancer. 2009;52(5):571-4.
Bayram, I., Erbey, F., Celik, N., Nelson, J. L., & Tanyeli, A. (2009). The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. Pediatric Blood & Cancer, 52(5), 571-4. https://doi.org/10.1002/pbc.21852
Bayram I, et al. The Use of a Protein and Energy Dense Eicosapentaenoic Acid Containing Supplement for Malignancy-related Weight Loss in Children. Pediatr Blood Cancer. 2009;52(5):571-4. PubMed PMID: 19090549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. AU - Bayram,Ibrahim, AU - Erbey,Fatih, AU - Celik,Nilgun, AU - Nelson,Jeffrey L, AU - Tanyeli,Atila, PY - 2008/12/19/entrez PY - 2008/12/19/pubmed PY - 2009/4/7/medline SP - 571 EP - 4 JF - Pediatric blood & cancer JO - Pediatr Blood Cancer VL - 52 IS - 5 N2 - BACKGROUND: The aim of nutritional therapy in cancer patients is to prevent weight loss and to improve functional capacity and quality of life. Clinical studies however, have continued to demonstrate that a reduction in body weight loss is difficult to achieve in cancer cachexia. Several studies have shown that supplementation with eicosapentaenoic acid (EPA), an omega-3 fatty acid, has anti-cachectic effects in adult cancer patients. This study evaluated the clinical effects of a protein and energy dense EPA containing nutritional supplement in a group of pediatric cancer patients receiving active chemotherapy treatment. METHODS: The study was a prospective, randomized, single center, open-label design. Fifty-two patients diagnosed with pediatric malignant disease and receiving intensive chemotherapy were included. Thirty-three patients received a nutritional supplement containing EPA in addition to their regular food intake. Nineteen control patients did not receive supplementation. Patients were examined and their data (body weight, body mass index, and weight percentile) were recorded regularly once a month for 3 months. A subgroup of patients was evaluated for 6 months. RESULTS: At 3 months, there were significantly fewer patients in the treatment group as compared to controls that showed losses in body weight (P = 0.001), BMI (P = 0.002), and a negative deviation in weight percentile (P = 0.021). In addition, remission rate was significantly (P = 0.036) higher in the treatment group as compared to controls. CONCLUSIONS: This study demonstrates a decrease in cancer-induced weight loss in pediatric patients fed a protein and energy dense nutrition supplement containing EPA. SN - 1545-5017 UR - https://www.unboundmedicine.com/medline/citation/19090549/The_use_of_a_protein_and_energy_dense_eicosapentaenoic_acid_containing_supplement_for_malignancy_related_weight_loss_in_children_ L2 - https://doi.org/10.1002/pbc.21852 DB - PRIME DP - Unbound Medicine ER -